June 14, 2017 / 11:13 AM / a month ago

Johnson & Johnson's flu drug succeeds in mid-stage trial

1 Min Read

June 14 (Reuters) - Johnson & Johnson said on Wednesday its experimental flu drug significantly reduced viral load compared to a placebo in a mid-stage study of patients with a type of influenza.

Study data also showed that adding J&J's drug, pimodivir, to a widely-used flu treatment called oseltamivir resulted in a significantly lower viral load in some patients, compared to those who received pimodivir alone. (Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below